Logo

Dicerna Closes $25M Series B

Aug 12, 2010
Premium

Dicerna Pharmaceuticals said that it has closed a $25 million Series B round of financing, which will provide the company with the money needed to advance its lead oncology drug-development program, as well as other pipeline efforts.

Dicerna said it would also use the funds to further develop its delivery technologies.

The round was led by a new investor, Domain Associates, and included existing investors Oxford Bioscience Partners, Skyline Ventures, and Abingworth.

Dicerna first disclosed that it was planning the Series B round to Gene Silencing News in May (GSN 5/13/2010).

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
Dicerna
Breaking News
The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.